Kayla Babb-Dicus
Family · Sikeston, MONPI 1508484890
Payments from drug & device makers
Across 217 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$520
- Otsuka America Pharmaceutical, Inc.$394
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$339
- Sunovion Pharmaceuticals Inc.$324
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$219
- Neurocrine Biosciences, Inc.$212
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,50499%
- Education$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,542 in reported general payments places this provider in the 85th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 263 | $79,796 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $38,463 |
| LybalviOlanzapine/Samidorphan Malate | 28 | $21,753 |
| EntrestoSacubitril/Valsartan | 42 | $14,333 |
| InvokanaCanagliflozin | 45 | $13,350 |
| XareltoRivaroxaban | 41 | $11,885 |
| RexultiBrexpiprazole | 12 | $11,778 |
| MounjaroTirzepatide | 11 | $10,663 |
| NeuproRotigotine | 14 | $10,283 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 55 | $9,500 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 112 | $8,730 |
| MyrbetriqMirabegron | 27 | $8,724 |
| JanuviaSitagliptin Phosphate | 18 | $7,884 |
| JardianceEmpagliflozin | 22 | $6,999 |
| Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc | 67 | $6,932 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $26 | $38,46357 claims |
| Johnson & JohnsonInvokana, Xarelto | $68 | $25,23486 claims |
| Alkermes, Inc.Lybalvi | $520 | $21,75328 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $394 | $11,77812 claims |
| Lilly USA, LLCMounjaro | $118 | $10,66311 claims |
| Astellas Pharma US IncMyrbetriq | $35 | $8,72427 claims |
| MerckJanuvia | $47 | $7,88418 claims |
| Boehringer IngelheimJardiance | $129 | $6,99922 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $62 | $6,15713 claims |
| AbbVieNamzaric | $69 | $4,71115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,812 family providers in Missouri.
Other family in Sikeston
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.